PRGO

#2045
Perrigo Company plc Ordinary Shares
10.7 0 USD
+9574.50%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
10.60
10.72
Jahresspanne
0.11
22.01
Tagesänderung
+9574.50%
Monatliche Änderung
-9.86%
6 month change
-22.41%
Jahresänderung
-50.28%
Vorheriger Schlusskurs
0.1 1
Open
10.6 3
Tief
10.6 0
High
10.7 2
Volumen
145
Vollständige Grafik anzeigen Full chart

Financials

Übersicht Finanzbericht Statistik Dividenden
Vierteljährlich Jährlich
  • Market Capitalization 1.48 B
  • Employee 8 100
  • Founded N/A
  • CEO Murray S. Kessler
  • Website www.perrigo.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Arzneimittelhersteller – spezialisierte und Generika
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
-0.74
Preis-Umsatz-Verhältnis
0.32
Dividende je Aktie
0.29
Dividendenrendite in %
20.88

Perrigo Company plc Ordinary Shares

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.

Nachrichten